Drug Transporters. Группа авторовЧитать онлайн книгу.
on id="u49fa55ca-1cdb-55aa-84f1-e2060864c7e7">
Table of Contents
1 Cover
7 PREFACE
8 1 OVERVIEW OF DRUG TRANSPORTER FAMILIES 1.1 INTRODUCTION 1.2 WHAT ARE DRUG TRANSPORTERS? 1.3 STRUCTURE AND MODEL OF DRUG TRANSPORTERS 1.4 TRANSPORT MECHANISMS 1.5 POLARIZED EXPRESSION OF DRUG TRANSPORTERS IN BARRIER EPITHELIUM 1.6 CLASSIFICATIONS OF DRUG TRANSPORTERS 1.7 NOMENCLATURE OF DRUG TRANSPORTERS 1.8 REGULATION OF DRUG TRANSPORTERS 1.9 CONCLUSION REFERENCES
9 2 ORGANIC CATION AND ZWITTERION TRANSPORTERS 2.1 OVERALL INTRODUCTORY SECTION CATION TRANSPORTERS: OCT1, OCT2, OCT3 (OTHER SECTION: SLC19A2, SLC19A3, PMAT) 2.2 INTRODUCTION TO THE OCT FAMILY 2.3 OCT1 2.4 OCT2 2.5 OCT3 2.6 OTHER IMPORTANT CATION TRANSPORTERS: SLC19A2, SLC19A3 (THIAMINE TRANSPORTERS), SLC29A4 (MONOAMINE TRANSPORTER) ZWITTERION TRANSPORTERS: OCTN1, OCTN2, SLC22A15 AND SLC22A16 (OTHER SECTION: OCTN3) 2.7 INTRODUCTION TO THE ZWITTERION TRANSPORTERS 2.8 OCTN1 2.9 OCTN2 2.10 SLC22A15 2.11 SLC22A16 (FLIPT2, CT2, OCT6) 2.12 OCTN3 2.13 CONCLUSION REFERENCES
10 3 MULTIDRUG AND TOXIN EXTRUSION PROTEINS 3.1 INTRODUCTION 3.2 TISSUE AND SUBCELLULAR DISTRIBUTION 3.3 TRANSPORT ACTIVITY 3.4 STRUCTURE 3.5 EXPRESSION AND REGULATION 3.6 DRUG EFFICACY AND TOXICITY 3.7 PHARMACOGENETICS 3.8 CONCLUSIONS ACKNOWLEDGMENT REFERENCES
11 4 ORGANIC ANION TRANSPORTERS (OATs) 4.1 OAT FAMILY 4.2 MOLECULAR CHARACTERIZATION 4.3 EXPRESSION AND REGULATION OF OATS 4.4 OAT SUBSTRATES AND DRUG–DRUG (DRUG–METABOLITE) INTERACTION 4.5 SYSTEMS BIOLOGY OF OATS 4.6 CONCLUSIONS ACKNOWLEDGMENTS REFERENCES
12 5 ORGANIC ANION TRANSPORTING POLYPEPTIDES OATP 5.1 INTRODUCTION TO THE OATP SUPERFAMILY 5.2 MOLECULAR CHARACTERISTICS OF OATPS 5.3 EXPRESSION AND REGULATION OF OATPS 5.4 OATP SUBSTRATES, INHIBITORS, AND STIMULATORS 5.5 PHARMACOLOGY OF OATPS 5.6 PHYSIOLOGY AND PATHOPHYSIOLOGY OF OATPS 5.7 CONCLUSIONS ACKNOWLEDGMENTS REFERENCES
13 6 MAMMALIAN OLIGOPEPTIDE TRANSPORTERS 6.1 INTRODUCTION 6.2 OLIGOPEPTIDE TRANSPORTERS 6.3 FUNCTIONAL PROPERTIES 6.4 REGULATION 6.5 PHARMACEUTICAL DRUG SCREENING 6.6 CONCLUDING REMARKS REFERENCES